Introduction {#s1}
============

Patients who have undergone radiotherapy and/or chemotherapy, including childhood cancer survivors (CCS), are predisposed to various endocrinological complications ([@r1], [@r2]). In addition, those who received hematopoietic stem cell transplantation (HSCT) are considered to be at high risk for developing endocrinopathies, including GH deficiency, primary hypothyroidism, and primary hypogonadism ([@r2],[@r3],[@r4]).

In addition to endocrinopathies, metabolic derangements have emerged as important, under-recognized, late complications in patients who underwent HSCT. In 2000, impaired glucose intolerance and dyslipidemia were discerned as late effects of HSCT in children ([@r5]). Furthermore, reports have confirmed the association between HSCT and aberrations in glucose/lipid metabolism ([@r6],[@r7],[@r8],[@r9],[@r10],[@r11]), which include central or abdominal obesity ([@r5], [@r7], [@r10]), insulin resistance ([@r5], [@r8], [@r9]), diabetes ([@r5], [@r6], [@r10], [@r11]), hypertriglyceridemia ([@r5], [@r9], [@r10]), and fatty liver disease ([@r8], [@r10]). These metabolic derangements can develop in the absence of obesity or a high body mass index (BMI) ([@r5], [@r7], [@r8], [@r11]), and are associated with total body irradiation (TBI) performed for HSCT conditioning, but not with chemotherapeutic agents ([@r6], [@r7], [@r11]).

An analysis by Wei *et al*. ([@r12]) of 30 CCS with acute lymphoblastic leukemia (ALL) who had undergone HSCT demonstrated a higher incidence of glucose intolerance with insulin resistance compared with non-HSCT CCS with ALL and obese controls. They also identified a lower lean mass, and higher visceral and lower subcutaneous fat among the patients following HSCT, describing their phenotype as "lipodystrophic and sarcopenic" ([@r12]). In our previous study ([@r13]), we reported five CCS who developed severe insulin resistance and hypertriglyceridemia following HSCT, with a partial lipodystrophic phenotype that markedly resembled Dunnigan-type familial partial lipodystrophy (familial partial lipodystrophy type 2, OMIM \#151660).

Despite the aforementioned studies, partial lipodystrophy following HSCT has rarely been reported ([@r13], [@r14]). The difficulty in diagnosing partial lipodystrophy, mainly due to the absence of both diagnostic criteria and biomarkers, is likely the main reason for limited reports. However, we consider that the lipodystrophic phenotype is an important study target, as it indicates that adipose tissue has become damaged through HSCT, and adipocyte dysfunction is closely related to the pathogenesis of metabolic derangements following HSCT ([@r6], [@r7], [@r9], [@r11]).

The present study aimed to investigate the prevalence of partial lipodystrophy among patients following HSCT by performing a cross-sectional survey in a local children's hospital. In addition, an extraction of risk factors was attempted for the development of partial lipodystrophy following HSCT.

Materials and Methods {#s2}
=====================

Study population
----------------

The target population in this study was patients who had undergone HSCT to treat malignant disease or benign hematological disorders, such as pure red-cell anemia, aplastic anemia, or myelodysplastic syndrome. Those patients whose latest HSCT was \< 24 mo from study initiation were excluded, to avoid confusing poor nutrition immediately following HSCT with the lipodystrophic phenotype.

In April 2014, the candidate patients were extracted from the institutional medical record database. After excluding the patients who showed relapse and/or died and those lost to follow-up, 110 patients were confirmed as the primary target population. Of these 110 patients, 108 underwent HSCT in our hospital. Two patients who had undergone HSCT in other hospitals were also included in the study. Three patients with Down syndrome were excluded, in an attempt to depict the metabolic characteristics clearly in the patients with lipodystrophy. Three patients with severe medical conditions, including chronic heart failure (n = 1) with cardiomyopathy and chronic respiratory failure (n = 2) due to pulmonary fibrosis, were considered unsuitable for study participation. Therefore, 104 patients were asked to participate in this study.

Experiments
-----------

An experienced clinician (MA) evaluated the study participants in the outpatient setting of the Pediatric Endocrinology Clinic from April 2014 to March 2016. Height and weight were measured in the upright position using a certified electronic scale. Waist circumference was measured using a measuring tape at the umbilical level. Blood pressure (BP) was recorded in the sitting position. Pediatric radiologists evaluated the presence of fatty liver disease using ultrasonography or computed tomography (CT) imaging. Patient histories were obtained by searching medical records. Prolonged immunosuppressant administration was arbitrarily defined as the administration of any immunosuppressant for \>37 mo, based on the finding that the median duration of immunosuppression therapy for chronic graft-versus-host disease (GVHD) among the study participants was 20.3 mo (range: 4.0--155 mo, n = 36).

The diagnostic criteria for partial lipodystrophy were based on our previous observation that five patients developed partial lipodystrophy resembling Dunnigan-type familial partial lipodystrophy following HSCT ([@r13]). First, on a clinical inspection, partial lipodystrophy was suspected when definite lipohypertrophy of either the cheek or neck was recognized by findings such as a Cushingoid appearance or double chin ([@r15]), as well as simultaneous recognition of definite lipoatrophy of the gluteal region. The diagnosis of partial lipodystrophy was confirmed when overt diabetes and/or ultrasonography- or CT-proven fatty liver disease were detected.

To define overt diabetes, the diagnostic criteria of the Japan Diabetes Society were adopted ([@r16]). Patients with a fasting blood glucose level of 126 mg/dL and concomitant elevated glycated hemoglobin (HbA1c) levels (≥ 6.5%) were diagnosed with overt diabetes. In cases where the HbA1c level was \< 6.5%, a repeatedly high fasting blood glucose level was sufficient for the diagnosis of overt diabetes.

A high BMI was defined as \> 22 kg/m^2^ in adults and \> 90^th^ percentile in children using national standards ([@r17]). Hypertension was defined according to the Guideline for the Management of Hypertension 2014, developed by the Japanese Society of Hypertension ([@r18]).

After obtaining patient consent, fasting blood samples were collected. For patients receiving antidiabetics or lipid-lowering medications, a 3-month cessation of medication was requested before sampling. Low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), triglycerides, HbA1c, and insulin were measured at an in-house laboratory. Serum leptin levels were determined using a Human-Leptin radioimmunoassay (EMD Millipore, Darmstadt, Germany). Total adiponectin was measured with a latex turbidimetric immunoassay using a Human Adiponectin Latex Kit (LSI Medience Corporation, Tokyo, Japan). Serum levels of tumor necrosis factor-alpha (TNF-α) were measured with the Human TNF-alpha Quantikine HS ELISA (R&D Systems, Inc., Minneapolis, USA). The homeostatic model assessment of insulin resistance (HOMA-R) was calculated by the following formula: fasting glucose (mg/dL) × insulin (µIU/mL)/405

Statistics
----------

Normally distributed data are presented as the mean with standard deviation; non-normally distributed data are presented as the median with range. To compare the clinical properties between participants and non-participants, as well as those between patients with and without lipodystrophy, an unpaired T-test, Mann-Whitney U-test, Chi-square test, or Fisher's probability test was performed according to the parametric/non-parametric nature of the data and the number of samples. Parametric data included the age at recruitment and the age at evaluation. To compare the metabolic profiles between patients with and without lipodystrophy, an unpaired T-test, Mann-Whitney U-test, or Fisher's probability test was employed, where triglycerides, HOMA-R, and leptin concentrations were treated as non-parametric data. Statistical analysis was performed using the IBM SPSS Statistics version 23 (IBM Corporation, New York, NY, USA). A P-value of \< 0.05 was considered significant.

Ethical issues
--------------

The study design was approved by the Institutional Ethical Committee of Kanagawa Children's Medical Center in January 2014 (permission number 82-06). This study was registered in the University Hospital Medical Information Network Clinical trial registry in February 2014 as UMIN000013087. Written informed consent was obtained from the patients and/or their caregivers depending on the patient's age and cognitive ability.

Results {#s3}
=======

Participant clinical profiles
-----------------------------

Of the 104 patients who were asked to participate in the study, 65 agreed to enroll until March 2016. Ten patients showed relapse and/or died during the study period. The remaining 29 patients did not participate due to patient's or parental refusal. The profile of the participants compared with that of the non-participants is described in [Table 1](#tbl_001){ref-type="table"}Table 1Comparison of the profiles between study participants and non-participants. Although male predominance was observed in the non-participants, no other differences were noted between the participants and non-participants.

Incidence of partial lipodystrophy
----------------------------------

Nine patients were suspected to have a lipodystrophic phenotype resembling Dunnigan-type familial partial lipodystrophy based on the findings of gluteal lipoatrophy and lipohypertrophy of the cheeks and/or neck. Of these patients, six were found to have fatty liver disease and, therefore, were regarded as having developed partial lipodystrophy according to our criteria. Among the six patients with partial lipodystrophy, three patients met the criteria for overt diabetes. The profile of these six patients is described in [Table 2](#tbl_002){ref-type="table"}Table 2Comparison of the clinical profiles between patients with and without lipodystrophy, as compared with the profile of those who did not meet the criteria.

Clinical characteristics of the patients with partial lipodystrophy
-------------------------------------------------------------------

Patients with partial lipodystrophy were significantly older at evaluation compared with those without partial lipodystrophy ([Table 2](#tbl_002){ref-type="table"} and [Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Age distribution of the participants at evaluation (n = 65). Black bars correspond to patients with partial lipodystrophy, whereas gray bars indicate patients without lipodystrophy.; P \< 0.01). Similarly, patients with partial lipodystrophy showed a significantly longer elapsed time following the first HSCT compared with those without partial lipodystrophy ([Table 2](#tbl_002){ref-type="table"} and [Fig. 2](#fig_002){ref-type="fig"}Fig. 2.Distribution of the years elapsed since the initial HSCT (n = 65). Black bars correspond to patients with partial lipodystrophy, whereas gray bars indicate patients without lipodystrophy.; P \< 0.01).

In addition, recurrence of the underlying malignant disease (P \< 0.05) and multiple HSCTs (P \< 0.05) were frequently observed in patients with partial lipodystrophy, as compared with those without partial lipodystrophy.

Disease category, types of HSCT, TBI, cranial irradiation, and prolonged immunosuppressant administration were not significantly different between the patients with lipodystrophy and those without (P \> 0.05). However, all patients with lipodystrophy had received TBI.

Metabolic aspects of the participants
-------------------------------------

As is shown in [Table 3](#tbl_003){ref-type="table"}Table 3Comparison of metabolic profiles between patients with and without lipodystrophy, approximately two-thirds of the participants agreed to undergo fasting blood sampling. Compared with the patients without lipodystrophy, those with lipodystrophy were found to have significantly elevated systolic and diastolic BP (P \< 0.01), a high incidence of hypertension (P \< 0.05), significantly elevated LDL-C levels (P \< 0.01), and significantly elevated triglyceride levels (P \< 0.01).

Adiponectin levels were significantly lower in patients with lipodystrophy compared with the patients without lipodystrophy (P \< 0.01), whereas serum leptin and TNF-α levels were not significantly different between the two groups. HOMA-R was significantly higher in patients with lipodystrophy (P \< 0.01).

Three of the six patients with lipodystrophy had developed overt diabetes: at the time of investigation, one patient was on metformin (500 mg a day with HbA1c 6.5%), whereas the remaining two patients were instructed to modify their lifestyle. One lipodystrophic patient without overt diabetes was on statin therapy, and her fasting glucose levels were mildly elevated (111 mg/dL). Among the patients without lipodystrophy, only one patient had diabetes and was treated by lifestyle modification.

Discussion {#s4}
==========

The present study performed a cross-sectional survey in a local children's hospital in Japan and demonstrated that the prevalence of partial lipodystrophy resembling the Dunnigan-type was 9.2% among CCS and the patients with hematological disorders who have undergone HSCT. In addition, HSCT-related lipodystrophy was frequently found in the patients of older age, in those with longer elapsed time following HSCT, in those with a history of disease recurrence, and multiple HSCTs. This is the first systematic study to investigate the lipodystrophic phenotype in this population.

The absence of a gold standard diagnostic method, as well as the absence of useful diagnostic biomarkers, confounds the confirmation of partial lipodystrophy, especially in its acquired form where gene analyses serve no purpose ([@r15], [@r19],[@r20],[@r21],[@r22]). In this study, criteria for the diagnosis of partial lipodystrophy were devised as follows: affirmation of abnormal subcutaneous fat distribution evidenced by lipohypertrophy in the cheek and/or neck as well as gluteal lipoatrophy, and the presence of fatty liver disease and/or overt diabetes.

Of the nine patients with suspected lipodystrophy, six were shown to have fatty liver disease, thus confirming that the clinical assessment had a high specificity for ascertaining lipodystrophy, and that over-diagnosis of lipodystrophy was unlikely. In addition, three of the four patients with overt diabetes were judged as having lipodystrophy, indicating high sensitivity. Accordingly, we assume that our criteria for the diagnosis of partial lipodystrophy were acceptable. Possibly, overt diabetes may not be necessary for the diagnostic criteria, considering that diabetes is not directly related to abnormal fat distribution.

The 9.2% prevalence of lipodystrophy in this study may be an overestimation since a substantial number of the patients had moved to adult hospitals or were lost to follow-up. There is also the potential that patients with any concurrent medical problems, such as dyslipidemia, would have preferred to stay in the hospital where HSCT was performed. In addition, those with a history of disease recurrence and those who had undergone multiple HSCTs showed a higher incidence of lipodystrophy. Those patients with a complicated disease course may also have preferred to undergo follow-up in the children's hospital. We have no reasonable explanation for the difference in sex proportions between the participants and non-participants. Obviously, the true incidence of lipodystrophy should be determined through a large-scale, prospective study.

All patients with lipodystrophy had received TBI of 10--14 Gy as the conditioning procedure prior to HSCT. In previous reports of HSCT-related lipodystrophy ([@r9], [@r10], [@r12], [@r14]), including our study ([@r13]), all patients had undergone TBI. Mayson *et al*. ([@r9]) suggested that TBI might deplete the number of pre-adipocytes, which would inhibit fat-tissue expandability, leading to severe insulin resistance and hypertriglyceridemia. In addition, the association between TBI, but not chemotherapeutic agents, and diabetes and/or dyslipidemia following HSCT ([@r6], [@r7], [@r11]) supports the causative role for TBI in the development of lipodystrophy. An animal study suggested that subcutaneous adipose tissue is very sensitive to TBI ([@r23]). In addition, *ob/ob* mice that received 8 Gy TBI developed reduced body-fat mass with more severe insulin resistance and hepatic steatosis compared with controls ([@r24]). Together, these results suggest that TBI is a prerequisite for the development of HSCT-related partial lipodystrophy.

The present study aimed to identify other risk factors for the development of partial lipodystrophy among patients following HSCT. Although a multivariate analysis could not be applied due to the small sample size, a significant difference in the elapsed time following HSCT, as well as in the age at evaluation, was observed between patients with and without lipodystrophy. This suggests that the probability of developing partial lipodystrophy increases as a patient ages and that a long latent period is required to develop a lipodystrophic phenotype. Consistent with this, in our six patients with lipodystrophy, \> 9 yr had elapsed since the initial HSCT. This observation is in accordance with previous reports, in which almost a decade was necessary for either lipodystrophy or diabetes to develop following HSCT ([@r9], [@r10], [@r12],[@r13],[@r14]).

Here, we discuss the relationship between HSCT-related partial lipodystrophy and hitherto reported metabolic aberrations following TBI. Previous studies have recurrently demonstrated that TBI can cause central obesity ([@r5], [@r7], [@r10]), insulin resistance ([@r5], [@r8], [@r9]), diabetes ([@r5], [@r6], [@r10], [@r11]), hypertriglyceridemia ([@r5], [@r9], [@r10]), and fatty liver disease ([@r8], [@r10]), even in patients with a low-to-normal BMI ([@r5], [@r7], [@r8], [@r11]). Some authors have suggested that these features resemble the phenotype of partial lipodystrophy. However, partial lipodystrophy following HSCT has rarely been reported ([@r9], [@r10], [@r12],[@r13],[@r14]). We suggest that this discrepancy derives from both the poor recognition of lipodystrophy as a disease entity and the challenges associated with the diagnosis of partial lipodystrophy. Accordingly, the metabolic aberrations and partial lipodystrophy following HSCT may be the same condition caused by adipocyte damage from TBI.

Disease recurrence and multiple HSCTs were more common in patients with lipodystrophy compared with patients without lipodystrophy. In addition, although not significant, a history of prolonged immunosuppressive treatment was also recurrently found in patients with lipodystrophy. Collectively, patients with lipodystrophy tended to have a complicated disease course. While TBI may be the main culprit for adipose tissue damage, chemotherapeutic agents, chronic GVHD itself and/or immunosuppressants may have had some role in the disease progression.

Our study indicates that patients with partial lipodystrophy following HSCT are at a high risk of developing metabolic complications, including elevated BP, higher LDL-C and triglyceride levels, elevated HOMA-R, diabetes, and fatty liver disease. These results indicated that HSCT-related partial lipodystrophy might influence the development of premature atherosclerosis, as with other forms of lipodystrophy ([@r15], [@r21]).

Patients with lipodystrophy had decreased adiponectin levels, which is consistent with a previous report showing low adiponectin levels in ALL patients following HSCT compared with those treated with chemotherapy only ([@r12]). Considering that hypoadiponectinemia plays a pivotal role in the development of insulin resistance, dyslipidemia, and hypertension in metabolic syndrome ([@r25]), it is tempting to believe that hypoadiponectinemia is one of the major factors to induce metabolic complications found in partial lipodystrophy following HSCT. Although we measured TNF-α as a representative inflammatory cytokine, no difference in circulating TNF-α levels was observed between the patients with lipodystrophy and those without. However, marked metabolic derangements found in our patients strongly suggest an involvement of inflammatory cytokines. A more comprehensive evaluation is needed for determining the causative role of cytokines.

The present study had several limitations. First, our study population was rather small and considerably heterogeneous in terms of age and elapsed time period from HSCT. Second, as mentioned previously, the incidence of lipodystrophy (9.2%) may have been biased. Third, although endocrinological complications may have some roles in the development of lipodystrophy, a thorough analysis of endocrinopathies was not possible because of limited access to the patients. However, thyroid and gonadal function were routinely screened in the majority of the patients. Therefore, the presence of severe hypothyroidism or untreated hypogonadism does not seem likely.

The reliability of the diagnosis of partial lipodystrophy is the final limitation of this study. As discussed previously, we assume that our criteria for partial lipodystrophy had satisfactory sensitivity and specificity. However, the judgment of regional lipoatrophy and lipohypertrophy depended solely on subjective observation. Development of a new biomarker for partial lipodystrophy, which is more accurate than plasma adiponectin or lipid levels, will be very helpful. This biomarker will also facilitate an early ascertainment of lipodystrophy, coupled with the increased recognition of partial lipodystrophy as a disease entity among clinicians caring for patients following HSCT.

Conclusion {#s5}
==========

A substantial number of patients developed partial lipodystrophy resembling the Dunnigan-type at a later period following HSCT, and this was associated with unfavorable metabolic profiles. All patients with lipodystrophy had received TBI, which may be the main cause of adipose tissue dysfunction.
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